BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Iberdomide

First Posted Date: 2023-06-12

Last Posted Date: 2024-07-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT05899738

Locations: 🇺🇸
Local Institution - 0001, Daytona Beach, Florida, United States

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy Female Volunteers

Interventions: Drug: BMS-986196
Drug: Loestrin

First Posted Date: 2023-06-06

Last Posted Date: 2023-09-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT05891262

Locations: 🇺🇸
Altasciences, Cypress, California, United States

A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Phase 4

Recruiting

Conditions: Anemia

Interventions: Biological: Luspatercept

First Posted Date: 2023-06-06

Last Posted Date: 2024-11-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT05891249

Locations: 🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳
Local Institution - 0011, New Delhi, Delhi, India
🇮🇳
Vedanta Institute Of Medical Sciences, Ahmedabad, Gujarat, India

and more 10 locations

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986449
Drug: Nivolumab

First Posted Date: 2023-06-05

Last Posted Date: 2024-10-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT05888831

Locations: 🇳🇱
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL), Amsterdam, Noord-Holland, Netherlands
🇺🇸
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States
🇺🇸
Yale New Haven Hospital-Smilow Cancer Center, New Haven, Connecticut, United States

and more 19 locations

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Famotidine
Drug: Afimetoran

First Posted Date: 2023-05-19

Last Posted Date: 2024-01-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT05866627

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986196
Drug: Caffeine
Drug: Montelukast
Drug: Flurbiprofen
Drug: Omeprazole
Drug: Midazolam
Drug: Digoxin
Drug: Pravastatin

First Posted Date: 2023-05-10

Last Posted Date: 2023-09-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT05852769

Locations: 🇺🇸
ICON plc, Millcreek, Utah, United States

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]BMS-986419

First Posted Date: 2023-05-06

Last Posted Date: 2023-10-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT05847439

Locations: 🇺🇸
Labcorp Clinical Research Unit - Madison, Madison, Wisconsin, United States

DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation

Not Applicable

Completed

Conditions: Atrial Fibrillation
Atrial Flutter

Interventions: Diagnostic Test: 14-days continuous ECG monitoring
Diagnostic Test: Risk prediction model

First Posted Date: 2023-05-03

Last Posted Date: 2024-05-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2112

Registration Number: NCT05838781

Locations: 🇸🇪
Karolinska Institutet Danderyd University Hospital, Stockholm, Outside US, Sweden
🇸🇪
Halland Hospital Varberg, Varberg, Outside US, Sweden

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Iberdomide
Drug: Lenalidomide

First Posted Date: 2023-04-24

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1216

Registration Number: NCT05827016

Locations: 🇫🇷
CHU Hôpital Sud, Amiens Cedex 1, France
🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

and more 264 locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986325
Drug: Placebo

First Posted Date: 2023-04-14

Last Posted Date: 2023-11-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT05813717

Locations: 🇺🇸
Local Institution - 0001, Cypress, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy